Newsletter | February 22, 2024

02.22.24 -- Kriya Therapeutics' Announcements At JPM

SPONSOR

As the patient’s immune cells are the starting materials, inherent biological variability leads to CAR-T manufacturing. Additional critical raw materials also have batch-to-batch variability, which means the entire production process is a constant balancing act of adjusting the manufacturing process to create standardized manufacturing. Join Cell & Gene Live for a discussion on practical ways to overcome the challenges associated with batch-to-batch variation. Registration is free thanks to the support of Entegris.

FROM THE EDITOR

Kriya Therapeutics' Announcements At JPM

Following JPM 2024, Cell & Gene Chief Editor Erin Harris caught up with Kriya Therapeutics' Dr. Shankar Ramaswamy to discuss the company's announcements as they relate to its pipeline of gene therapies.

FEATURED EDITORIAL

Cell And Gene Therapies: Regulatory Opportunities In 2024

Despite the promise of cell and gene therapies, the regulations governing them seem to lag. This article explores how sponsors and industry groups can work with regulatory agencies to improve communication, promote regulatory clarity, and even help to shape policy.

INDUSTRY INSIGHTS

Optimized Fill/Finish To Limit DMSO’s Negative Impact On T Cells

In order to improve the existing cryopreservation paradigm, operators must consider fill/finish and cryopreservation techniques that streamline processing steps and minimize cells’ exposure to DMSO.

Optimizing Project Communication Strategies

Communication within projects can be challenging, as many individuals are involved, and we all absorb information differently. Learn how to communicate more effectively with your stakeholders.

How CDMOs Have Become Emerging Technology Influencers

Unearth how CDMOs fill the gap between cutting-edge science and the commercial sector of CGT by partnering with the best technology providers to maximize the manufacturing process.

A Solution For Recruiting And Retaining Rare Disease Patients

Millions of people suffer from rare diseases, yet clinical trials often fail to recruit enough patients because they live too far away from sites. Hybrid trial designs offer a patient-centered solution.

Resolve Spectral Mixing With Customizable Cell Mimics

Explore the standard flow cytometry workflow and which controls are a best fit for your projects that will contribute to a confident data analysis.

Managing Change In Clinical Trials: The Data Management Playbook

Gain insight into how better planning for change related to the most critical element of trials – the data to support a therapy submission – can save substantial time, money, and resources.

Primary Clarification Of Lentiviral Vector With Low-Shear Separation

Evaluate the performance of a cell harvesting system using data on the titer recovery and turbidity during the downstream processing and clarification of lentiviral vectors.

Supporting Multiple Global Gene Therapy Studies For Rare Diseases

See how these CGT experts were able to address many complicated challenges – including site start-up issues, stringent regulatory requirements, and the logistics of handling highly sensitive genetic material.

SOLUTIONS

A Plug-And Play, Ready In Minutes, In-Line Multiparameter PAT Platform

Powerfully Simple Digital PCR

Leading The Genomic Medicine Revolution

Connect With Cell & Gene: